EXEL: Expanding franchises, clinical innovation, and AI-driven efficiency fuel growth and market leadership
Key priorities include expanding product franchises in RCC and NETs, with CABOMETYX and zanzalintinib driving growth through new indications and robust clinical development. Market share gains, disciplined R&D spending, and broad AI adoption support strong financial and operational outlooks.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.